SLC5A2 and type 2 diabetes mellitus: SGLT2 inhibitors currently approved or under investigation include dapagliflozin, canagliflozin, empagliflozin and ipragliflozin; this manuscript will focus on the efficacy and safety of the highly selective and reversible SGLT2 inhibitor dapagliflozin, primarily in patients with T2DM.